Suppression of Colon Tumorigenesis in Mutant <i>Apc</i> Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-CateninKevin J. Lee, Gary A. Piazza, Wen‐Chi Chang et al.|Cancer Prevention Research|2021Cited by 19
Abstract A30: Novel non-COX inhibitory sulindac derivative with PDE10 inhibitory activity reduces incidence and multiplicity of colorectal adenomas in the APC+/min-FCCC mouse modelKevin J. Lee, Wen‐Chi Chang, Xi Chen et al.|Cancer Research|2017Cited by 1
Abstract 1140: Characterization of a novel PDE10 inhibitor in lung tumor cells and an orthotopic mouse model of lung cancerVerónica Ramírez‐Alcántara, Gary A. Piazza, Bing Zhu et al.|Cancer Research|2017Cited by 1
Abstract 5159: Characterization of a novel class of RAS inhibitory compounds with potent anti-tumor activityAntonio Ward, Adam B. Keeton, Xi Chen et al.|Cancer Research|2017Cited by 0
Abstract 5243: Novel non-COX inhibitory sulindac derivative with β-catenin suppressing activity reduces the formation of colorectal adenomas and adenocarcinomas in the <i>APC</i> <i>+/min-FCCC</i> mouse modelKevin J. Lee, Wen‐Chi Chang, Xi Chen et al.|Cancer Research|2017Cited by 0